The long-term effect of cisplatin on renal function
- PMID: 3756770
- DOI: 10.1002/1097-0142(19861115)58:10<2214::aid-cncr2820581009>3.0.co;2-i
The long-term effect of cisplatin on renal function
Abstract
The long-term effect of cisplatin on renal function was studied in a follow-up investigation, 16 to 52 months after chemotherapy in 22 patients with disseminated nonseminomatous testicular cancer. The median cumulated cisplatin dose was 452 mg/m2 (range, 275-650 mg/m2). Prehydration with isotonic saline secured diuresis above 100 ml/hour. GFR (glomerular filtration rate: 51Cr-EDTA clearance) fell by 12.5% (median, P less than 0.01) compared with the pretreatment level. Effective renal plasma flow (125I-hippuran clearance) was estimated to be likewise reduced. The serum creatinine level rose 8 mumol/1 (median, P less than 0.05) during the treatment period with no further rise afterwards. Serum magnesium and urinary excretion of beta-2-microglobulin were normal. The results indicate a moderate and permanent reduction in GFR with no signs of long-term tubular defects in patients treated with cisplatin.
Similar articles
-
Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.Cancer. 1983 Jun 1;51(11):2035-40. doi: 10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>3.0.co;2-8. Cancer. 1983. PMID: 6340821
-
Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?J Urol. 2013 Dec;190(6):2081-5. doi: 10.1016/j.juro.2013.06.009. Epub 2013 Jun 11. J Urol. 2013. PMID: 23764076
-
Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.Cancer Chemother Pharmacol. 1988;21(2):163-7. doi: 10.1007/BF00257365. Cancer Chemother Pharmacol. 1988. PMID: 3280153
-
Cisplatin nephrotoxicity: experimental and clinical studies.Dan Med Bull. 1990 Feb;37(1):1-12. Dan Med Bull. 1990. PMID: 2178884 Review.
-
Platinum organ toxicity and possible prevention in patients with testicular cancer.Int J Cancer. 1999 Dec 10;83(6):866-9. doi: 10.1002/(sici)1097-0215(19991210)83:6<866::aid-ijc34>3.0.co;2-9. Int J Cancer. 1999. PMID: 10597214 Review.
Cited by
-
Renal function related to different treatment modalities for malignant germ cell tumours.Br J Cancer. 1990 Nov;62(5):842-6. doi: 10.1038/bjc.1990.391. Br J Cancer. 1990. PMID: 2173944 Free PMC article.
-
A risk-benefit assessment of amifostine in cytoprotection.Drug Saf. 1999 Nov;21(5):367-87. doi: 10.2165/00002018-199921050-00003. Drug Saf. 1999. PMID: 10554052 Review.
-
Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.Mediterr J Hematol Infect Dis. 2023 Sep 1;15(1):e2023051. doi: 10.4084/MJHID.2023.051. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37705524 Free PMC article. Review.
-
Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.Cancer Chemother Pharmacol. 2016 Feb;77(2):281-8. doi: 10.1007/s00280-016-2966-1. Epub 2016 Jan 20. Cancer Chemother Pharmacol. 2016. PMID: 26791871 Free PMC article.
-
Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.Cancer Chemother Pharmacol. 1990;27(1):55-9. doi: 10.1007/BF00689277. Cancer Chemother Pharmacol. 1990. PMID: 2245493
MeSH terms
Substances
LinkOut - more resources
Research Materials